Cite
Royce M, Osgood CL, Amatya AK, et al. FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer. Clin Cancer Res. 2021;doi: 10.1158/1078-0432.CCR-21-3247.
Royce, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Chang, C. J. G., Ricks, T. K., Shetty, K. A., Kraft, J., Qiu, J., Song, P., Charlab, R., Yu, J., King, K. E., Rastogi, A., Janelsins, B., Weinberg, W. C., Clouse, K., Borders-Hemphill, V., Brown, L., Gomez-Broughton, C., Li, Z., Nguyen, T. T., Qiu, Z., Ly, A. T., Chang, S., Gao, T., Tu, C. M., King-Kallimanis, B., Pierce, W. F., Chiang, K., Lee, C., Goldberg, K. B., Leighton, J. K., Tang, S., Pazdur, R., Beaver, J. A., & Amiri-Kordestani, L. (2021). FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, . https://doi.org/10.1158/1078-0432.CCR-21-3247
Royce, Melanie, et al. "FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. (2021). doi: https://doi.org/10.1158/1078-0432.CCR-21-3247
Royce M, Osgood CL, Amatya AK, Fiero MH, Chang CJG, Ricks TK, Shetty KA, Kraft J, Qiu J, Song P, Charlab R, Yu J, King KE, Rastogi A, Janelsins B, Weinberg WC, Clouse K, Borders-Hemphill V, Brown L, Gomez-Broughton C, Li Z, Nguyen TT, Qiu Z, Ly AT, Chang S, Gao T, Tu CM, King-Kallimanis B, Pierce WF, Chiang K, Lee C, Goldberg KB, Leighton JK, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L. FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer. Clin Cancer Res. 2021 Dec 16; doi: 10.1158/1078-0432.CCR-21-3247. Epub 2021 Dec 16. PMID: 34916216.
Copy
Download .nbib